Stivarga 40 mg film-coated tablets
Sponsors
Agenus Inc., Bristol Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Centre Hospitalier Regional Universitaire
Conditions
Advanced CancerAdvanced solid tumorAdvanced solid tumors (squamous cell carcinoma of the head and neck
(SCCHN)Advanced/metastatic colorectal cancerBone sarcomaColorectal Cancer (CRC)Colorectal cancer spread at distanceMelanoma
Phase 1
A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
CompletedCTIS2023-508954-25-00
Start: 2022-05-11End: 2024-08-20Target: 96Updated: 2024-06-19
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
RecruitingCTIS2025-520743-33-00
Start: 2025-07-23Target: 69Updated: 2025-07-21
Phase 2
A Randomized, Open-label, Phase 2 study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
Active, not recruitingCTIS2022-502065-23-00
Start: 2023-06-01Target: 102Updated: 2025-06-24
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
Regorafenib for recurrent grade 2 and 3 meningioma. A multicenter, randomized phase II study (MIRAGE trial)
RecruitingCTIS2024-510954-28-01
Start: 2024-09-23Target: 104Updated: 2025-03-11
REGOBONE_A Randomized Phase II, placebo-controlled, multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas
Active, not recruitingCTIS2024-513455-33-00
Start: 2014-09-11Target: 159Updated: 2024-08-09
Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients. The PARERE trial
Active, not recruitingCTIS2024-513296-41-00
Start: 2020-12-03Target: 214Updated: 2024-09-16
A phase-2 clinical trial of regorafenib in patients with pretreated advanced melanoma
RecruitingCTIS2024-514087-11-02
Start: 2022-10-03Target: 87Updated: 2025-03-17
Evaluation of treatment PERSOnalization based on its therapeutic monitoring in patients with metastatic colorectal cancer treated with regorafenib
CompletedCTIS2024-517241-13-00
Start: 2021-10-22End: 2025-04-11Target: 110Updated: 2025-02-07
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
Target: 250Updated: 2024-11-06
Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2
Not yet recruitingCTIS2024-519669-23-00
Target: 60Updated: 2025-10-02
Phase 3
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixeddose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
CompletedCTIS2023-503797-21-00
Start: 2022-08-10End: 2025-07-14Target: 233Updated: 2025-06-26
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers
RecruitingCTIS2023-509761-21-00
Start: 2024-07-08Target: 174Updated: 2024-08-28
A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1.
Active, not recruitingCTIS2024-512555-21-00
Start: 2019-09-18Target: 78Updated: 2025-10-29
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Active, not recruitingCTIS2024-512915-33-00
Start: 2022-12-22Target: 328Updated: 2026-01-04
A Phase 3 Multicenter, Randomized, Openlabel, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
Active, not recruitingCTIS2024-511187-81-00
Start: 2022-03-28Target: 99Updated: 2025-07-17